| 000 | 01684 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250513194548.0 | ||
| 264 | 0 | _c20000124 | |
| 008 | 200001s 0 0 eng d | ||
| 022 | _a0764-4469 | ||
| 024 | 7 |
_a10.1016/s0764-4469(00)80037-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aArimondo, P B | |
| 245 | 0 | 0 |
_aTargeting topoisomerase I cleavage to specific sequences of DNA by triple helix-forming oligonucleotide conjugates. A comparison between a rebeccamycin derivative and camptothecin. _h[electronic resource] |
| 260 |
_bComptes rendus de l'Academie des sciences. Serie III, Sciences de la vie _cSep 1999 |
||
| 300 |
_a785-90 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAminoglycosides |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xchemistry |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xchemistry |
| 650 | 0 | 4 | _aBase Sequence |
| 650 | 0 | 4 |
_aCamptothecin _xchemistry |
| 650 | 0 | 4 |
_aDNA Topoisomerases, Type I _xmetabolism |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMolecular Sequence Data |
| 650 | 0 | 4 | _aNucleic Acid Conformation |
| 650 | 0 | 4 |
_aOligodeoxyribonucleotides _xchemistry |
| 650 | 0 | 4 | _aSubstrate Specificity |
| 650 | 0 | 4 | _aTopoisomerase I Inhibitors |
| 700 | 1 | _aBailly, C | |
| 700 | 1 | _aBoutorine, A | |
| 700 | 1 | _aSun, J S | |
| 700 | 1 | _aGarestier, T | |
| 700 | 1 | _aHélène, C | |
| 773 | 0 |
_tComptes rendus de l'Academie des sciences. Serie III, Sciences de la vie _gvol. 322 _gno. 9 _gp. 785-90 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0764-4469(00)80037-2 _zAvailable from publisher's website |
| 999 |
_c10504402 _d10504402 |
||